Related Articles
ONDANSETRON VERSUS METOCLOPRAMIDE IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING - A METAANALYSIS
Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis
5-HT3 ANTAGONIST ONDANSETRON FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN AN OUTPATIENT POPULATION
Emetic control in breast cancer patients receiving iv CMF